SLS (SELLAS Life Sciences Group) Cash per Share: $0.59 (As of Mar. 2026)

What is SELLAS Life Sciences Group Cash per Share?

SELLAS Life Sciences Group SLS -5.52% 25 Cash per Share is $0.59 as of Mar. 2026. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). SELLAS Life Sciences Group's Cash per Share for the quarter that ended in Mar. 2026 was $0.59.

SELLAS Life Sciences Group (NAS:SLS) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

SELLAS Life Sciences Group Cash per Share Related Terms

SELLAS Life Sciences Group Cash per Share Historical Data

* Premium members only.

The historical data trend for SELLAS Life Sciences Group's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group Cash per Share Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

1.34

0.82

0.08

0.19

0.47

SELLAS Life Sciences Group Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															0.31	0.25	0.35	0.47	0.59

25GF Score

SELLAS Life Sciences Group Inc SLS

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

SELLAS Life Sciences Group Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

SELLAS Life Sciences Group's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	71.793	/	153.10
	=	0.47

SELLAS Life Sciences Group's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	107.097	/	181.33
	=	0.59

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $0.59 mean?

SELLAS Life Sciences Group (SLS) has a Cash per Share of $0.59 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for SELLAS Life Sciences Group and its competitors.

Is SELLAS Life Sciences Group's Cash per Share too high?

SELLAS Life Sciences Group's current Cash per Share is $0.59. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.

How does SELLAS Life Sciences Group's Cash per Share compare to MBX and BHVN?

SELLAS Life Sciences Group's Cash per Share of $0.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Biotechnology company?

A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for SELLAS Life Sciences Group and its competitors. SELLAS Life Sciences Group's current Cash per Share is $0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is SELLAS Life Sciences Group stock overvalued right now?

SELLAS Life Sciences Group (SLS) has a current Cash per Share of $0.59. The current Cash per Share is $0.59. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Cash per Share is $0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SELLAS Life Sciences Group Business Description

Industry Healthcare Biotechnology

Comparable Companies MBX BHVN PHVS NRIX VCEL MLYS NTLA TRVI IMNM AGIO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges RXK3:Germany

Address 7 Times Square, Suite 2503, New York, NY, USA, 10036

Website https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

25GF Score

Get the complete analysis for SLS

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.76

Price

View SLS Analysis

See Cash per Share data for all stocks →